Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
Therapeutic Advances in Gastroenterology
by Laurent Peyrin-Biroulet, William J. Sandborn, Remo Panaccione, Eugeni Domènech, Lieven Pouillon, Britta Siegmund, Silvio Danese, Subrata Ghosh
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments for ulcerative colitis and/or Crohn’s disease: infliximab, adalimumab, golimumab and certolizumab pegol. Despite the clear benefits of tumour necrosis factor-α inhibitors, a subset of patients with inflammatory bowel disease either d ..read more
Visit website
The relationship between Helicobacter pylori infection and reflux esophagitis and the long-term effects of eradication of Helicobacter pylori on reflux esophagitis
Therapeutic Advances in Gastroenterology
by Mariko Hojo, Kumiko Ueda, Tsutomu Takeda, Yoichi Akazawa, Hiroya Ueyama, Yuji Shimada, Daisuke Asaoka, Akihito Nagahara
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Introduction:Whether the incidence of reflux esophagitis (RE) increases after the eradication of Helicobacter pylori (H. pylori) is controversial. Few reports have evaluated the presence or absence of RE after a long period of time, taking into account the degree of atrophy and/or administration of acid secretion inhibitors. We investigated the relationship between H. pylori and RE taking into account these factors.Methods:This was a retrospective cohort study with approval by the Ethics Committee. Patients who ..read more
Visit website
Surgical treatment of metastatic VIPoma: a case report
Therapeutic Advances in Gastroenterology
by Azadeh Azizian, Alexander König, Amelie Hartmann, Frank Schuppert, Ali Seif Amir Hosseini, Julia Kitz, Michael Ghadimi
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. VIPoma, a neuroendocrine tumour mostly occurring in the human pancreas and producing high levels of vasoactive intestinal peptide, is a rare disease that presents with a wide spectrum of symptoms, including intense diarrhoea, hypokalaemia, and cardiac complications, with life-threatening consequences. In most cases, metastatic lesions are present at VIPoma diagnosis. Treatment options include symptomatic therapy, chemotherapy, radiation and surgery. Due to its low incidence, there are no evidence-based therapy ..read more
Visit website
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies
Therapeutic Advances in Gastroenterology
by Charlie W. Lees, J. Jasper Deuring, Michael Chiorean, Marco Daperno, Gianluca Bonfanti, Rebecca Germino, Pritha Bhadra Brown, Irene Modesto, Roger A. Edwards
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Introduction:Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Outcome prediction based on early treatment response, along with clinical and laboratory variables, would be very useful for clinical practice. The aim of this study was to determine early variables predictive of responder status in patients with UC treated with tofacitinib.Methods:Data were collected from patients treated with tofacitinib 10 mg twice daily in the OCTAVE Induction 1 and 2 stu ..read more
Visit website
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
Therapeutic Advances in Gastroenterology
by Michaela Melde, Tanja M. Müller, Ines Schneider, Carol-Immanuel Geppert, Laura Mühl, Laura Besendorf, Clarissa Allner, Emily Becker, Imke Atreya, Francesco Vitali, Raja Atreya, Markus F. Neurath, Sebastian Zundler
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Background:The anti-α4β7 integrin antibody vedolizumab is an established therapeutic option for the treatment of inflammatory bowel disease (IBD). It has also been successfully used in patients with chronic antibiotic-refractory pouchitis following proctocolectomey with ileal pouch-anal anastomosis. However, the expression and function of gut-homing markers as well as strategies to predict the response to vedolizumab in pouchitis are understudied so far.Methods:We used flow cytometry and dynamic adhesion assays ..read more
Visit website
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
Therapeutic Advances in Gastroenterology
by Carlos Taxonera, María Pilar Martínez-Montiel, Manuel Barreiro-de-Acosta, Isabel Vera, Rufo Lorente, Pablo Vega, María Teresa Diz-Lois, Ana María Fuentes Coronel, José Lázaro Pérez Calle, Begoña Casis, Rocío Ferreiro-Iglesias, Marta Calvo, David Olivares, Cristina Alba
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Background:A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of inflammatory bowel disease (IBD) patients after switching their ADA regimen from 40 mg weekly to 80 mg EOW given with a single-dose pen.Methods:In this multicentre cross-sectional study, patients in whom the ADA regimen w ..read more
Visit website
Endoscopic ultrasound-guided ethanol and radiofrequency ablation of pancreatic insulinomas: a systematic literature review
Therapeutic Advances in Gastroenterology
by Ghassan El Sayed, Levente Frim, Jamie Franklin, Raymond McCrudden, Charles Gordon, Safa Al-Shamma, Szabolcs Kiss, Péter Hegyi, Bálint Erőss, Péter Jenő Hegyi
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Background:Insulinoma is the most common neuroendocrine neoplasm of the pancreas, characterised by hypoglycaemic symptoms. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and ethanol ablation (EUS-EA) are novel methods for treating insulinoma.We aimed to perform a systematic review to assess the efficacy and safety of EUS-guided ablation techniques for pancreatic insulinomas.Methods:We systematically searched for articles detailing EUS-guided ablations of insulinomas. We performed a qualitative a ..read more
Visit website
Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis
Therapeutic Advances in Gastroenterology
by Daniel Segna, Nele Brusselaers, Damian Glaus, Niklas Krupka, Benjamin Misselwitz
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Introduction:The use of proton-pump inhibitors (PPI) may be associated with an increased risk of gastric cancer (GC).Objective:To review and meta-analyse available literature investigating the association between PPI use and GC risk.Methods:Two independent reviewers systematically searched Ovid MEDLINE, EMBASE, and Cochrane Library (inception to July 2020) for case-control and cohort studies assessing the association between PPI use and GC according to a predefined protocol in PROSPERO (CRD42018102536). Reviewe ..read more
Visit website
Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic
Therapeutic Advances in Gastroenterology
by Henit Yanai, Hadar Amir Barak, Jacob E Ollech, Irit Avni Biron, Idan Goren, Yifat Snir, Hagar Banai Eran, Yelena Broitman, Maya Aharoni Golan, Elena Didkovsky, Iris Amitay-Laish, Ayelet Ollech, Emmilia Hodak, Iris Dotan, Lev Pavlovsky
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Background and Aims:Skin eruptions are prevalent among patients with inflammatory bowel diseases (IBD), often associated with therapies and frequently leading to dermatological consults and treatment interruptions. We aimed to assess the impact of joint shared decision-making in a multidisciplinary (MDT) IBD-DERMA clinic.Methods:This retrospective cohort study assessed a consecutive group of patients with IBD who were referred for consultation in an MDT clinic at a tertiary referral center in Israel.Results:Ove ..read more
Visit website
Primary tumor location (right versus left side of the colon) and resection affect the survival of patients with liver metastases from colonic neuroendocrine carcinoma: a population-based study
Therapeutic Advances in Gastroenterology
by Wen Cai, Weiting Ge, Jiawei Zhang, Siyuan Xie, Dehao Wu, Hanguang Hu, Jianshan Mao
1y ago
Therapeutic Advances in Gastroenterology, Volume 14, Issue , January-December 2021. Background:Colonic neuroendocrine carcinomas (co-NECs) are heterogeneous and aggressive, especially with regard to metastasis. Whether co-NECs on the right and left sides of the colon have different characteristics from colon adenocarcinoma is unknown.Methods:The co-NEC patients were selected from the 2010–2017 Surveillance, Epidemiology, and End Results Program (SEER) database. The right and left sides of the colon were separated by the splenic flexure. Coarsened exact matching (CEM) was performed to adjust fo ..read more
Visit website

Follow Therapeutic Advances in Gastroenterology on Feedspot

Continue with Google
OR